These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

111 related items for PubMed ID: 3583552

  • 1. Deferoxamine for the treatment of hemosiderosis during CAPD.
    Gomez RA, Campbell F, Savory J, Chevalier RL.
    Int J Pediatr Nephrol; 1987; 8(1):21-4. PubMed ID: 3583552
    [Abstract] [Full Text] [Related]

  • 2. [Deferoxamine B treatment of hemosiderosis in the anephric patient undergoing hemodialysis].
    Ceriati F, Cavicchioni C, Marino IR, Pomponi M.
    Chir Patol Sper; 1981 Feb; 29(1):14-9. PubMed ID: 7344858
    [No Abstract] [Full Text] [Related]

  • 3. [Chronic aluminum poisoning in continuous ambulatory peritoneal dialysis: treatment with deferoxamine].
    Passlick J, Wilhelm M, Busch T, Grabensee B, Ohnesorge FK.
    Dtsch Med Wochenschr; 1989 Feb 17; 114(7):253-7. PubMed ID: 2917487
    [Abstract] [Full Text] [Related]

  • 4. Iron overload, but not treatment with desferrioxamine favours the development of septicemia in patients on maintenance hemodialysis.
    Seifert A, von Herrath D, Schaefer K.
    Q J Med; 1987 Dec 17; 65(248):1015-24. PubMed ID: 3455553
    [Abstract] [Full Text] [Related]

  • 5. Hemosiderosis in a patient on regular hemodialysis: treatment by desferrioxamine.
    Baker LR, Barnett MD, Brozovic B, Cattell WR, Ackrill P, McAlister J, Nimmon C.
    Clin Nephrol; 1976 Jul 17; 6(1):326-8. PubMed ID: 954239
    [Abstract] [Full Text] [Related]

  • 6. Continuous ambulatory peritoneal dialysis- a new dimension in the treatment of end-stage renal disease.
    Shohat J, Boner G, Rosenfeld J, Waller A, Iaina A, Eliahou HE.
    Isr J Med Sci; 1982 Oct 17; 18(10):1014-8. PubMed ID: 7174268
    [Abstract] [Full Text] [Related]

  • 7. [Deferoxamine in hemosiderosis. Fecal iron excretion during continuous subcutaneous infusion].
    Krüger N, Kijewski H, König R, Tillmann W, Schröter W.
    Dtsch Med Wochenschr; 1984 Nov 02; 109(44):1682-5. PubMed ID: 6489181
    [Abstract] [Full Text] [Related]

  • 8. Iron chelating therapy in thalassemia: current problems.
    Russo G.
    Haematologica; 1990 Nov 02; 75 Suppl 5():84-8. PubMed ID: 2086385
    [No Abstract] [Full Text] [Related]

  • 9. [Iron-overload in patients on maintenance hemodialysis: diagnostic criteria, indications and treatment by desferrioxamine (author's transl)].
    Simon P, Bonn F, Guezennec M, Tanquerel T, Ksang.
    Nephrologie; 1981 Nov 02; 2(4):165-70. PubMed ID: 7329501
    [Abstract] [Full Text] [Related]

  • 10. Deferoxamine-enhanced fecal losses of aluminum and iron in a patient undergoing continuous ambulatory peritoneal dialysis.
    McCarthy JT, Kurtz SB, Mussman GV.
    Am J Med; 1987 Feb 02; 82(2):367-70. PubMed ID: 3812538
    [Abstract] [Full Text] [Related]

  • 11. [Continuous ambulatory peritoneal dialysis].
    Nomoto Y.
    Gan To Kagaku Ryoho; 1995 Dec 02; 22 Suppl 4():425-8. PubMed ID: 8849287
    [Abstract] [Full Text] [Related]

  • 12. Residual renal function in children treated with continuous ambulatory peritoneal dialysis or automated peritoneal dialysis--a preliminary study.
    Roszkowska-Blaim M, Skrzypczyk P, Drozdz D, Pietrzyk JA.
    Adv Perit Dial; 2009 Dec 02; 25():103-9. PubMed ID: 19886329
    [Abstract] [Full Text] [Related]

  • 13. Removal of trace metals by continuous ambulatory peritoneal dialysis after desferrioxamine B chelation therapy.
    Navarro JA, Granadillo VA, Rodríguez-Iturbe B, García R, Salgado O, Romero RA.
    Clin Nephrol; 1991 May 02; 35(5):213-7. PubMed ID: 1855329
    [Abstract] [Full Text] [Related]

  • 14. Intraperitoneal deferoxamine therapy for iron overload in children undergoing CAPD.
    Andreoli SP, Cohen M.
    Kidney Int; 1989 Jun 02; 35(6):1330-5. PubMed ID: 2770113
    [Abstract] [Full Text] [Related]

  • 15. [Role of continuous ambulatory peritoneal dialysis (CAPD) in a program for the treatment of chronic renal insufficiency. Problems posed by transfer of CAPD to transplantation or hemodialysis].
    Canaud B, Mion C.
    Nephrologie; 1995 Jun 02; 16(1):129-35. PubMed ID: 7700413
    [Abstract] [Full Text] [Related]

  • 16. Continuous peritoneal dialysis for children: a decade of worldwide growth and development.
    Alexander SR, Honda M.
    Kidney Int Suppl; 1993 Feb 02; 40():S65-74. PubMed ID: 8445841
    [Abstract] [Full Text] [Related]

  • 17. A comparative study of continuous ambulatory peritoneal dialysis and center hemodialysis. Efficacy, complications, and outcome in the treatment of end-stage renal disease.
    Charytan C, Spinowitz BS, Galler M.
    Arch Intern Med; 1986 Jun 02; 146(6):1138-43. PubMed ID: 3718101
    [Abstract] [Full Text] [Related]

  • 18. Long-term efficacy of deferoxamine iron chelation therapy in adults with acquired transfusional iron overload.
    Schafer AI, Rabinowe S, Le Boff MS, Bridges K, Cheron RG, Dluhy R.
    Arch Intern Med; 1985 Jul 02; 145(7):1217-21. PubMed ID: 3925909
    [Abstract] [Full Text] [Related]

  • 19. Continuous high-dose intravenous desferrioxamine treatment for iron overload.
    Sidi Y, Shaklai M, Liban E, Pinkhas J.
    Isr J Med Sci; 1981 May 02; 17(5):348-51. PubMed ID: 7263191
    [Abstract] [Full Text] [Related]

  • 20. Hemosiderosis in a dialysis patient: treatment with hemofiltration and deferoxamine chelation therapy.
    McCarthy JT, Libertin CR, Mitchell JC, Fairbanks VF.
    Mayo Clin Proc; 1982 Jul 02; 57(7):439-41. PubMed ID: 7087549
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.